Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

2da, Ariad w/ '788. There are 194 million shares outstanding today, and if Ariad decides to take this path alone, there will be another 70 million shares added before '788 is approved, if approved. Remember, '788 just entered the clinic, and the chance of success is exceedingly small in phase I trials. It would violate the odds for Ariad to have a third successful compound. I expect Denner knows this and will make the right decision (SELL)...